WO2018097570A3 - Pharmaceutical formulation comprising dapagliflozin l-proline - Google Patents

Pharmaceutical formulation comprising dapagliflozin l-proline Download PDF

Info

Publication number
WO2018097570A3
WO2018097570A3 PCT/KR2017/013243 KR2017013243W WO2018097570A3 WO 2018097570 A3 WO2018097570 A3 WO 2018097570A3 KR 2017013243 W KR2017013243 W KR 2017013243W WO 2018097570 A3 WO2018097570 A3 WO 2018097570A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapagliflozin
proline
pharmaceutical formulation
present
diabetes
Prior art date
Application number
PCT/KR2017/013243
Other languages
French (fr)
Korean (ko)
Other versions
WO2018097570A2 (en
Inventor
권세호
김재호
김진철
김용일
박재현
우종수
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of WO2018097570A2 publication Critical patent/WO2018097570A2/en
Publication of WO2018097570A3 publication Critical patent/WO2018097570A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical formulation comprising dapagliflozin L-proline. The pharmaceutical formulation comprising dapagliflozin L-proline according to the present invention has excellent dissolution properties of active ingredients and exhibits high content uniformity. Therefore, the pharmaceutical formulation comprising dapagliflozin L-proline of the present invention can be used as a preventive or therapeutic agent, which has excellent quality and bioavailability, for diabetes, diabetes-related diseases, and diabetic complications.
PCT/KR2017/013243 2016-11-24 2017-11-21 Pharmaceutical formulation comprising dapagliflozin l-proline WO2018097570A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0157550 2016-11-24
KR1020160157550A KR20180058510A (en) 2016-11-24 2016-11-24 Pharmaceutical formulation comprising dapagliflozin l-proline

Publications (2)

Publication Number Publication Date
WO2018097570A2 WO2018097570A2 (en) 2018-05-31
WO2018097570A3 true WO2018097570A3 (en) 2018-08-09

Family

ID=62195318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013243 WO2018097570A2 (en) 2016-11-24 2017-11-21 Pharmaceutical formulation comprising dapagliflozin l-proline

Country Status (2)

Country Link
KR (1) KR20180058510A (en)
WO (1) WO2018097570A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110922372A (en) * 2019-11-04 2020-03-27 天津大学 Amino acid eutectic compound of dapagliflozin and preparation method thereof
KR20220007446A (en) * 2020-07-10 2022-01-18 한미약품 주식회사 Composite formulation comprising sitagliptin and dapagliflozin and a process for the preparation thereof
CR20230161A (en) * 2020-10-13 2023-09-21 Lg Chemical Ltd Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor
JP2024514184A (en) * 2021-04-14 2024-03-28 エルジー・ケム・リミテッド Pharmaceutical composition comprising a sphingosine-1-phosphate receptor agonist with controlled particle size
CN115343198A (en) * 2022-08-17 2022-11-15 扬子江药业集团上海海尼药业有限公司 Particle size determination method for dapagliflozin bulk drug

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (en) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
KR20110114658A (en) * 2009-02-13 2011-10-19 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
WO2015117538A1 (en) * 2014-02-10 2015-08-13 江苏豪森药业股份有限公司 New dapagliflozin crystalline form and preparation method therefor
KR20160034348A (en) * 2013-07-22 2016-03-29 산도즈 아게 Formulations containing amorphous dapagliflozin
WO2016147197A1 (en) * 2015-03-17 2016-09-22 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form
KR20160121190A (en) * 2015-04-10 2016-10-19 제이더블유중외제약 주식회사 Pharmaceutical composition comprising anagliptin or a pharmaceutically acceptable salt thereof, and metformin or a pharmaceutically acceptable salt thereof and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (en) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
KR20110114658A (en) * 2009-02-13 2011-10-19 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
KR20160034348A (en) * 2013-07-22 2016-03-29 산도즈 아게 Formulations containing amorphous dapagliflozin
WO2015117538A1 (en) * 2014-02-10 2015-08-13 江苏豪森药业股份有限公司 New dapagliflozin crystalline form and preparation method therefor
WO2016147197A1 (en) * 2015-03-17 2016-09-22 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form
KR20160121190A (en) * 2015-04-10 2016-10-19 제이더블유중외제약 주식회사 Pharmaceutical composition comprising anagliptin or a pharmaceutically acceptable salt thereof, and metformin or a pharmaceutically acceptable salt thereof and preparation method thereof

Also Published As

Publication number Publication date
KR20180058510A (en) 2018-06-01
WO2018097570A2 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2018097570A3 (en) Pharmaceutical formulation comprising dapagliflozin l-proline
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
MX2018005193A (en) Dual function proteins and pharmaceutical composition comprising same.
MX2020001403A (en) Quinoline derivatives for treating infections with helminths.
EP3659585A4 (en) Composition for delivering physiologically active ingredients into blood vessel
EP3643723A4 (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
MX2020001404A (en) Dihydrooxadiazinones.
WO2016126085A3 (en) Heterocyclic compound and pharmaceutical composition comprising same
EP3597208A4 (en) Pharmaceutical composition containing atpif1 for treatment of diabetes
WO2018084627A3 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2016142708A3 (en) Pharmaceutical composition
PH12019502655A1 (en) Acylated insulin compound
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
EP3909597A4 (en) Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient
EP3964520A4 (en) Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising same as active ingredient
EP3845516A4 (en) NOVEL HIF-1alfa INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT
EP3311817A4 (en) Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient
EP3610866A4 (en) Pharmaceutical composition for preventing and treating cancer, containing malate-aspartate shuttle inhibitor and anticancer drug as active ingredients
EP3586836A4 (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
WO2018060962A3 (en) Metformin amino acid compounds and methods of using the same
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EP3698801A4 (en) Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17874184

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17874184

Country of ref document: EP

Kind code of ref document: A2